StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$31.20−1.67 (-5.08%)

Close on Nov 18, 2026Market cap $1.73BP/E –Yield –

Maze Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Maze Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $167.50M. For fiscal 2024 it was $167.50M.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$167.50M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$20.00M-87.9%
Q2 FY2025Jun 30, 2025$0–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$2.50M–
Q2 FY2024Jun 30, 2024$165.00M–

More Maze Therapeutics figures

See a number that looks wrong?